Drug Development.

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, characterized by complex pathological processes.
• A multitarget drug design approach is crucial for effective AD treatment.
• Quinoline derivatives possess diverse biological activities, including antioxidant and Aβ-reducing properties, making them attractive for AD drug discovery.

Purpose of the Study:

• To design and synthesize novel quinoline-based compounds with anti-inflammatory and antioxidant activities for early-stage AD.
• To evaluate the drug-like properties, blood-brain barrier (BBB) permeability, and neuroprotective potential of these derivatives.

Main Methods:

• In silico evaluation of drug-like properties and BBB permeability.
• In vitro cytotoxicity and neuroprotection assays using microglial, astroglial, and neuronal cell lines against inflammatory and oxidative insults.
• In vivo toxicity and efficacy studies in Caenorhabditis elegans models.

Main Results:

• 80% of designed quinoline derivatives showed promising BBB permeability and high oral absorption potential.
• Two derivatives exhibited low toxicity (IC50 > 50 µM) and significant neuroprotection against oxidative stress at concentrations below 5 µM.
• These compounds demonstrated a tendency for neuroinflammatory protection and reduced nitric oxide production by 30%.

Conclusions:

• Designed quinoline derivatives possess favorable physicochemical properties for oral administration and BBB penetration.
• The compounds display significant antioxidant and anti-inflammatory effects, indicating potential as multitarget agents for AD prevention.
• These findings support further development of quinoline-based derivatives for Alzheimer's disease drug design.